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Open access under the ElseviEngagement of Toll-like receptor 4 (TLR4) by lipopolysaccharide (LPS) is a master trigger of the deleteri-
ous effects of septic shock. Horses and humans are considered the most sensitive species to septic shock,
but the mechanisms explaining these phenomena remain elusive. Analysis of tlr4 promoters revealed
high similarity among LPS-sensitive species (human, chimpanzee, and horse) and low similarity with
LPS-resistant species (mouse and rat). Four conserved nuclear factor kappa B (NFjB) binding sites were
found in the tlr4 promoter and two in the md2 promoter sequences that are likely to be targets for dexa-
methasone regulation. In vitro treatment of equine peripheral blood mononuclear cells (eqPBMC) with
LPS decreased transcripts of tlr4 and increased transcription of md2 (myeloid differentiation factor 2)
and cd14 (cluster of differentiation 14). Treatment with dexamethasone rescued transcription of tlr4 after
LPS inhibition. LPS-induced transcription of md2 was inhibited in the presence of dexamethasone. Dexa-
methasone alone did not affect transcription of tlr4 and md2.
 2013 Elsevier Inc. Open access under the Elsevier OA license. 1. Introduction
Humans and horses are among the most sensitive species to
endotoxemia and septic shock, presenting high mortality rates de-
spite treatment [1–3]. Septic shock is generally associated with
infection with lipopolysaccharide (LPS) containing gram-negative
bacteria. While mice require as much as 18 mg/kg of LPS to suc-
cumb to septic shock [4], humans will develop clinical signs of sys-
temic inﬂammatory reaction with as low as 2 ng/kg [5] and horses
will develop septic shock with 30 ng/kg [6].
Lipopolysaccharides are recognized by Toll-Like receptor 4
(TLR4) in combination with myeloid differentiation factor 2
(MD2) and cluster of differentiation 14 (CD14) [7–12]. The com-
plex formed by TLR4-MD2-CD14 signals through a conserved path-
way that results in the phosphorylation of nuclear factor kappa B
(NFjB) p65 subunit, which translocates into the nucleus and initi-.P. Bonin), baccarin@usp.br
l), laila@nahum.com.br (L.A.
camar@usp.br, mmcamar@g-
er OA license. ates transcription of several pro-inﬂammatory cytokines, such as
Interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-a) [13–
15]. These cytokines are responsible for the initiation of the innate
immune response, but also account for the pathogenesis of septic
shock and consequently affect mortality.
The alleged higher sensibility of humans and horses to septic
shock has generally been supported by anecdotal evidence. Studies
of tlr4 polymorphisms in both humans and horses found substitu-
tions in the TLR4 protein sequences. In the horse, none of them cor-
related with the inter-individual differences in TNF-a production
after LPS challenge in vitro [16]. On the other hand, in humans, it
was found that one of those substitutions interfere with LPS bind-
ing to the receptor ectodomain [17]. Still, to date there is no known
mechanism that explains why humans and horses are more sensi-
tive to LPS when compared to rodents.
Sequence similarity of tlr4, md2, and cd14 promoters among
mammals whose genome was completely sequenced were ana-
lyzed, including the conservation of NFjB binding sites. To validate
the functionality of these conserved NFjB binding sites, transcrip-
tion of tlr4, md2, and cd14 genes was studied in vitro after treat-
ment of equine peripheral blood mononuclear cells (eqPBMC)
with LPS and/or dexamethasone. A hypothesis that the anti-inﬂam-
matory drug dexamethasone acts by regulating the expression of
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tested in vitro.
2. Materials and methods
2.1. In silico analysis
Nucleotide sequences for the tlr4, md2 and cd14 genes contain-
ing a 50UTR region of 2 kb upstream the transcription initiation site
were retrieved from Ensembl [18] (Table 1). Global pairwise se-
quence alignments were performed using the rVISTA from the VIS-
TA package [19]. Analysis was performed looking for sequence
similarity patterns and conservation of NFjB binding sites across
selected sequences, using the horse sequence as reference.
2.2. Equine PBMC
Blood obtained from horses resident at the Veterinary School of
the University of São Paulo, Brazil, was used. The cohort included
both male and female horses of several breeds in the ages of 10–
20 years, all free from clinical signs of disease. All procedures were
carried out with the approval of the Institutional Animal Care and
Use Committee of the University of São Paulo (CEEA 01/2006).
Equine PBMC (eqPBMC) were obtained by centrifugation of blood
samples on Ficoll–Paque (GE Biosciences) according to the manu-
facturer’s instructions.
2.3. Lipopolysaccharide stimulation and dexamethasone treatment
PBMC were plated at 106 cells/mL in DMEM:F12 (1:1, v/v), 10%
heat-inactivated fetal calf serum (FCS), 2 mM L-glutamine, 50 lM
2-mercaptoethanol, 100 U/mL penicillin, 100 lg/mL streptomycin
(all from Life Technologies). For experiments using dexametha-
sone, cells were incubated for 90 min in the presence of different
concentrations of dexamethasone (Calbiochem) followed by stim-
ulation with 100 ng/mL ultra-pure LPS from Escherichia coli
O111:B4 (Invivogen, puriﬁed by enzymatic hydrolysis followed
by phenol–TEA–DOC extraction) (100 ng/mL equivalent to 10 EU/
mL). At established time-points, cells were harvested and pro-
cessed for qPCR.Table 1
Complete and annotated genes analyzed.
Species Genbank entry Gene
Homo sapiens-human GRCh37:9:120464610:120466609:1 tlr4
GRCh37:8:74901587:74903586:1 md2
GRCh37:5:140013256:140015255:-1 cd14
Equus caballus-horse EquCab2:25:21964163:21966162:1 tlr4
EquCab2:9:12574784:12576783:-1 md2
EquCab2:14:36267120:36269119:1 cd14
Pan troglodytes-
chimpanzee
CHIMP2.1:9:117237071:117239070:1 tlr4
CHIMP2.1:8:72435564:72437563:1 md2
CHIMP2.1:5:142392451:142394450:-1 cd14
Bos taurus-cow Btau_4.0:8:112424793:112426792:1 tlr4
Btau_4.0:Un.004.1:1344362:1346361:-
1
md2
Btau_4.0:7:51086967:51088966:-1 cd14
Mus musculus-mouse NCBIM37:4:66486645:66488644:1 tlr4
NCBIM37:1:16676514:16678513:1 md2
NCBIM37:18:36886391:36888390:-1 cd14
Sus scrofa-pig Sscrofa9:1:271619935:271621934:1 tlr4
Sscrofa9:4:64133466:64135465:-1 md2
Sscrofa9:2:129357849:129359848:-1 cd14
Rattus norvegicus-rat RGSC3.4:5:83562096:83564095:1 tlr4
RGSC3.4:5:1705241:1707240:-1 md2
RGSC3.4:18:29376329:29378328:-1 cd142.4. Transcripts quantiﬁcation
Total RNA was isolated from cells using Trizol. cDNA was gener-
ated using 200 ng of total RNA, oligo(dT) primers and Reverse
Transcriptase SuperScript III (all from Life Technologies). Expres-
sion levels of tlr4, md2, and cd14 mRNAs were measured by real-
time PCR (qPCR) using Quantifast SYBR green PCR kit (Qiagen)
and the primers listed in Table 2. Cycling conditions were one ini-
tial cycle of 95 C for 5 min, followed by 40 cycles of 95 C for 10 s
and 60 C for 30 s, plus one ﬁnal cycle of 95 C for 60 s followed by
55 C for 30 s and 95 C for 30 s. The qPCR products were of pre-
dicted sizes and yielded only one conserved peak at melting anal-
ysis (data not shown). The amount of speciﬁc mRNAs was
normalized as a ratio to the amount of equine GAPDH using the
2DDCT method as described by Livak and Schmittgen [20].
2.5. Statistical analysis
Change in transcripts for tlr4,md2, and cd14 from baseline were
measured at pre-determined time-points. Analysis with one-way
ANOVA followed by Bonferroni’s test indicated a statistically sig-
niﬁcant difference between time-points when p 6 0.05. IC50 was
calculated by curve regression (non-linear sigmoid dose–re-
sponse). All analyses were carried using Prism Graph 5.0 (Graph-
Pad Inc.).3. Results
3.1. Chimpanzee, horse, human, and pig promoters share sequence
similarity
To assess why humans and horses are more sensitive to septic
shock, we analyzed the tlr4, md2, and cd14 promoters among dif-
ferent mammals for sequence similarity. Sequences upstream the
transcription initiation sites of these genes were aligned. Only
annotated sequences from fully sequenced mammalian genomes
(chimpanzee, cow, horse, human, mouse, pig, and rat) were used
(Fig. 1). The similarity proﬁle of tlr4 promoters (Fig. 1A) revealed
that the horse tlr4 promoter shares extensive regions of similarity
with the pig sequence. A medium–high number of regions of sim-
ilarity were found when compared to the human and chimpanzee
promoters. Few regions of signiﬁcant similarity were found be-
tween the horse and cow promoters. Finally, only a small region
of sequence similarity was detected among the horse, rat, and
mouse promoters. Fig. 1(B) shows the regions of similarity be-
tween the horse md2 promoter and that of different species. As
seen before with the tlr4 promoter, the horse shares regions of sim-
ilarity within the md2 promoter with humans, chimpanzees and
pigs. However, in this particular case, it also shares similarity with
the cow promoter. Again, the regions of similarity between rat and
mouse were not signiﬁcant. Interestingly, when cd14 promoter was
analyzed, only one short region of signiﬁcant similarity was pres-
ent in all species (Fig. 1C).
3.2. tlr4 and md2 promoters contain conserved NFjB binding sites
The beneﬁcial effects from use of dexamethasone in human pa-
tients with sepsis [21,22] prompted us to focus our analyses on
conserved NFjB binding sites since this is the main effector tran-
scription factor resulting from TLR4 engagement. These binding
sites could be subject to dexamethasone inhibitory regulation
through the blockage of NFjB-p65 translocation caused by this
drug. The presence of conserved NFjB binding sites were therefore
analyzed, considering only those within the similar regions of all
sequences. Four conserved NFjB binding sites were found in the
Table 2
Primer sequences for qPCR.
Forward primer Reverse primer
eqTLR4 50-GGAACTGGACCTGAGCTTTA-30 50-CAATTTCACACCTGGACAAA-30
eqMD2 50-TAACATGAAGTCCCCGATTT-30 50-TCCCCTGAAGGAGAATGATA-30
eqCD14 50-GTTGTCAGTCAGTGCAGCTC-30 50-GAAGATGCTCCAGGAGAAGA-30
eqGAPDH 50-GCCCTCAATGACCACTTTGT-30 50-TTACTCCTTGGAGGCCATGT-30
Fig. 1. There are four conserved NFjB binding sites in the promoter region of tlr4 and two in the md2 promoter. (A–C) represent the multiple alignment of the promoters of
tlr4 (A),md2 (B), and cd14 (C) from analyzed species. The transcription initiation site is located on the left side of each sequence. The gray area represents regions of similarity
among sequences. (D) Shows that four conserved NFjB binding sites (indicated by arrows) were found in the promoter region of tlr4, two were found in the promoter ofmd2
and none was found in the promoter of cd14.
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promoter region of md2 gene. No conserved binding sites for NFjB
was found in the promoter region of cd14 (Fig. 1D).
3.3. LPS inhibits transcription of tlr4 but induces transcription of md2
and cd14 in vitro
To validate our in silico analysis, we performed a series of exper-
iments in vitro using PBMC from healthy horses (eqPBMC). The
horse was chosen because it represents an alternative animal mod-
el to sepsis studies and is, along with humans, the most sensitive
species to LPS among those whose genome is completely
sequenced.
The patterns of transcription of the genes coding for CD14, MD2
and TLR4 found in LPS-stimulated cultures of eqPBMC established
from three unrelated healthy horses (Fig. 2) were similar to those
patterns found in other mammals. The presence of LPS induced a
signiﬁcant decrease in the levels of tlr4 transcripts (p = 0.0035)
(Fig. 2, left panel) and an increase in md2 and cd14 transcripts
(Fig. 2, middle and right panels). The relative expression of the
tlr4 mRNA dropped to low levels after 8 h of LPS stimulation
whereas the relative expression of the md2 mRNA presented an
early peak at 8 h of stimulation and steady transcript levels for
24 h. CD14 transcripts increased earlier peaking at 4 h (Fig. 2, right
panel).3.4. tlr4,md2, and cd14 transcription is affected by dexamethasone
in vitro
EqPBMC obtained from three healthy donors were treated for
90 min with different concentrations of dexamethasone followed
by stimulation with LPS for 14 h. The basal levels (without LPS)
of in vitro transcripts of tlr4, md2 and cd14 were not affected by
the presence of different concentrations of dexamethasone
(Fig. 3). Dose–response curves for the relative levels of mRNAs in-
duced by LPS in eqPBMC pre-treated with dexamethasone sug-
gested a stimulatory effect of dexamethasone over tlr4 (Fig. 3,
left panel) and md2 (Fig. 3, middle panel) transcription whereas
an inhibitory effect was observed for the transcription of cd14
(IC50 = 4.17 M) (Fig. 3, right panel). The IC50 of dexamethasone
for TLR4 and MD2 were 1.37 M and 1.46 M, respectively.
3.5. LPS-induced inhibition of tlr4 transcription is reversed in vitro by
dexamethasone
The exposure of eqPBMC to LPS caused an initial decrease in tlr4
transcripts in the absence of dexamethasone (Fig. 2, left panel).
EqPBMC were treated with 10 7 M of dexamethasone for 90 min
before stimulation with 100 ng/mL of LPS. In the presence of
107 M dexamethasone, the cells regained transcriptional activity
for tlr4 and after 24 h its transcripts level corresponded to more
Fig. 2. LPS inhibits transcription of tlr4 but induces transcription of md2 and cd14 in vitro. PBMC was stimulated in vitro with 100 ng/mL of LPS. cDNA was ampliﬁed for tlr4
(round symbols), md2 (diamond symbols) and cd14 (square symbols) by qPCR. gapdh was ampliﬁed for normalization purposes. DDCT was calculated and expressed as fold
change in genes expression. The dotted line represents basal levels of transcription (before treatment). Data represents mean ± SD obtained from three unrelated horses for
tlr4 and md2 genes, and two unrelated horses for cd14. All experiments were performed in triplicates.
Fig. 3. LPS-induced transcription of tlr4, md2 and cd14 is affected in a dose–response fashion by dexamethasone in vitro. PBMC was cultured in the presence of different
concentrations of dexamethasone for 90 min, followed by 14 h of stimulation with 100 ng/mL LPS. cDNA was ampliﬁed for tlr4 (round symbols),md2 (diamond symbols) and
cd14 (square symbols) by qPCR. gapdh was ampliﬁed for normalization purposes. DDCT was calculated and expressed as fold change in gene expression. The dotted line
represents basal levels of transcription (before treatment). Data represents mean ± SD obtained from three unrelated horses assayed in triplicates.
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(p = 0.0262) (Fig. 4, left panel). Dexamethasone treatment had an
inhibitory effect in the LPS-induced md2 and cd14 transcripts
(p < 0.0001 and p = 0.0414, respectively) (Fig. 4, middle and right
panels). Compared to LPS stimulation alone (Fig. 2, middle panel),
in the presence of dexamethasone the peak of accumulation of
transcripts for md2 occurred sooner, at 1 h, and remained low
throughout the experimental period of 24 h (Fig. 4, middle panel).
The transcription of cd14, that peaked at 6 h after stimulation with
LPS alone (Fig. 2, right panel), showed a steady decrease in the
presence of dexamethasone (Fig. 3, right panel).4. Discussion
The engagement of TLRs triggers conserved signaling pathways
that result in downstream translocation of NFjB to the nucleus
[23–25]. Transcription of several pro-inﬂammatory cytokines,
including IL-1, IL-6, and TNF-a, depends on this NFjB translocation
[23,26]. Our ﬁnding of conserved NFjB binding sites in the mam-
malian promoters of tlr4 and md2, suggests that translocation of
NFjB might also play a role in the transcriptional regulation of
these genes. Furthermore, tlr4 and md2 promoters showed higher
similarity among LPS-sensitive species (chimpanzee, human, and
horse) than with LPS-resistant species (rat and mouse).
Two recent reports evaluated trials testing the efﬁcacy of low
doses of corticosteroids in the reversal of septic shock in human
patients, suggesting that they might reverse shock faster [21,22].
Another study focused on genes that are up- and down-regulated
by NFjB, and the effects of corticosteroids over the LPS-induced re-
sponse. Their results suggest that administration of corticosteroids
concomitantly with LPS infusion modiﬁes the initial transcriptionalproﬁle and is sufﬁcient to balance the resulting inﬂammatory re-
sponse towards a beneﬁcial outcome [27].
By blocking translocation of NFjB-p65 to the nucleus, dexa-
methasone inhibits transcription of several pro-inﬂammatory
cytokines [23,26]. Our ﬁnding that dexamethasone treatment, an
inhibitor of NFjB-p65 translocation, reversed the inhibitory effects
of LPS over the tlr4 transcription in vitro, suggests that NFjB plays a
negative effect over the regulation of this gene. On the other hand,
treatment with dexamethasone inhibited md2 transcription, sug-
gesting a positive effect by NFjB. It is conceivable to hypothesize
that by rescuing transcription of one major component of the
TLR4-MD2-CD14 complex, dexamethasone might be able to ame-
liorate, or perhaps reverse, the phenomenon referred to as ‘LPS tol-
erance’, when cells become non-responsive to LPS [28]. However, it
is important to point out that dexamethasone alone did not affect
the basal transcription of tlr4 and md2, suggesting that the basal
transcriptional machinery remains unaffected by the presence of
this drug. It is also notable that in another study, dexamethasone
did not affect the transcription levels of md2 when this was in-
duced by IL-6 [29].
Our results agree with those recently published showing that
NFjB binding sites can be tolerogenic in that they recruit a
repressosome containing NcorR-Hdac3-deacetylated-p50 to the
promoters of inﬂammatory genes [30]. The level of transcriptional
inhibition found in that study appeared to be dependent on the
number of NFjB motifs found in each promoter. Promoters with
four NFjB binding sites were the ones most strongly repressed
[30]. Our study found four conserved NFjB binding motifs in the
mammalian tlr4 promoter whereas only two were detected in
the md2 promoter. The ﬁnding that dexamethasone appeared to
recover the transcription of only tlr4 suggests that the tlr4 pro-
moter suffers active inhibition by a complex containing LPS-in-
duced NFjB-dependent members, possibly the repressosome
Fig. 4. LPS-induced inhibition of tlr4 transcription is reversed in vitro by dexamethasone. PBMC was cultured in the presence of 107 M dexamethasone for 90 min, followed
by LPS stimulation (100 ng/mL) for different time points. cDNA was ampliﬁed for tlr4 (round symbols), md2 (diamond symbols) and cd14 (square symbols) by qPCR. gapdh
was ampliﬁed for normalization purposes. DDCT was calculated and expressed as fold change in gene expression. The dotted line represents basal levels of transcription
(before treatment). Data represents mean ± SD obtained from three unrelated horses for tlr4, and two unrelated horses for md2 and cd14.
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that the cd14 promoter bears no NFjB binding sites, and accord-
ingly, suffered no inﬂuence of dexamethasone treatment before/
during the LPS challenge.
Finally, our analysis of tlr4 promoters places the horse in close
relationship to LPS-sensitive species such as humans, chimpanzees,
and pigs. In contrast, two species that are more resistant to septic
shock, rats and mice, presented very few and short regions of sim-
ilarity at the sequence level. Rodents are the most widely used ani-
mal models for studies of sepsis. Still, many promising therapeutic
protocols failed at reproducing in humans the same performance
they had in rodents, suggesting the existence of a ‘‘translational
disconnection’’ between these species [31]. Our results suggest
that studies of sepsis pathogenesis in the horse might provide
the answers that rodents failed short at. The disease progression
between human and horses share more similarities than with ro-
dents. The present study shows that at least some of these similar-
ities can be explained at the gene promoter level, making the horse
a better suited model for those studies aiming at unravelling the
pathogenesis of human sepsis.
In silico analysis of the tlr4,md2, and cd14 promoters from seven
mammalian species with completely sequenced and annotated
genomes uncovered the existence of four conserved NFjB binding
sites in the promoter of tlr4 and two in the promoter of md2. Se-
quence analysis showed that the horse tlr4 promoter has more re-
gions of similarity with humans, chimpanzees, and pigs than with
the promoter of cows, rats and mice. In vitro stimulation of
eqPBMC with LPS caused a decrease in the levels of transcripts
for tlr4 and increased transcripts for md2 and cd14. In vitro treat-
ment with dexamethasone rescued transcription of tlr4 after the
inhibition provoked by LPS, while inhibiting transcription of md2.
Dexamethasone treatment alone did not affect transcription of
tlr4 and md2. Altogether these data suggest that the NFjB binding
sites found in the promoters of tlr4 and md2 are functional and re-
spond to TLR4 engagement as a negative (for tlr4) and positive (for
md2) regulator of transcription of the receptor complex genes.Acknowledgments
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